MX2020005869A - Derivados de imidazopiridina y su uso como medicamento. - Google Patents

Derivados de imidazopiridina y su uso como medicamento.

Info

Publication number
MX2020005869A
MX2020005869A MX2020005869A MX2020005869A MX2020005869A MX 2020005869 A MX2020005869 A MX 2020005869A MX 2020005869 A MX2020005869 A MX 2020005869A MX 2020005869 A MX2020005869 A MX 2020005869A MX 2020005869 A MX2020005869 A MX 2020005869A
Authority
MX
Mexico
Prior art keywords
medicament
imidazopyridine derivatives
formula
nr2b
treatments
Prior art date
Application number
MX2020005869A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Roland Pfau
Georg Dahmann
Angelo Ceci
Cornelia Dorner-Ciossek
Riccardo Giovannini
Lothar Kussmaul
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2020005869A publication Critical patent/MX2020005869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con imidazopiridinas novedosas de la Fórmula A (VER FORMULA) procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en tratamientos, particularmente, en el tratamiento o prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
MX2020005869A 2017-12-08 2018-12-06 Derivados de imidazopiridina y su uso como medicamento. MX2020005869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206152 2017-12-08
PCT/EP2018/083728 WO2019110703A1 (en) 2017-12-08 2018-12-06 Imidazopyridine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
MX2020005869A true MX2020005869A (es) 2020-09-09

Family

ID=60629568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005869A MX2020005869A (es) 2017-12-08 2018-12-06 Derivados de imidazopiridina y su uso como medicamento.

Country Status (34)

Country Link
US (1) US10849907B2 (es)
EP (1) EP3720855B1 (es)
JP (1) JP6941235B2 (es)
KR (1) KR102728343B1 (es)
CN (1) CN111344291B (es)
AR (1) AR113923A1 (es)
AU (1) AU2018379438B2 (es)
BR (1) BR112020008583A2 (es)
CA (1) CA3083331A1 (es)
CL (1) CL2020001402A1 (es)
CO (1) CO2020006648A2 (es)
CY (1) CY1124744T1 (es)
DK (1) DK3720855T3 (es)
EA (1) EA202091139A1 (es)
ES (1) ES2897050T3 (es)
HR (1) HRP20211726T1 (es)
HU (1) HUE056667T2 (es)
IL (1) IL274868B2 (es)
LT (1) LT3720855T (es)
MA (1) MA51020B1 (es)
MX (1) MX2020005869A (es)
MY (1) MY203080A (es)
NZ (1) NZ763704A (es)
PE (1) PE20211454A1 (es)
PH (1) PH12020550785A1 (es)
PL (1) PL3720855T3 (es)
PT (1) PT3720855T (es)
RS (1) RS62517B1 (es)
SA (1) SA520412155B1 (es)
SG (1) SG11202005138TA (es)
SI (1) SI3720855T1 (es)
TW (1) TWI809014B (es)
UA (1) UA126247C2 (es)
WO (1) WO2019110703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
US11376258B2 (en) 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
TWI225488B (en) * 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
AU2005247699A1 (en) * 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
JP2010510245A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2014060398A1 (en) 2012-10-18 2014-04-24 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mglur5 receptor activity
CA2936886A1 (en) 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
TW201609741A (zh) * 2014-06-04 2016-03-16 盧郡控股（開曼）有限公司 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
RU2017107558A (ru) * 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b

Also Published As

Publication number Publication date
AU2018379438A1 (en) 2020-05-07
DK3720855T3 (da) 2021-11-08
ES2897050T3 (es) 2022-02-28
IL274868B2 (en) 2024-06-01
IL274868B1 (en) 2024-02-01
CY1124744T1 (el) 2022-07-22
US10849907B2 (en) 2020-12-01
PE20211454A1 (es) 2021-08-05
AU2018379438B2 (en) 2022-08-18
MA51020B1 (fr) 2021-10-29
CN111344291A (zh) 2020-06-26
CA3083331A1 (en) 2019-06-13
KR102728343B1 (ko) 2024-11-11
EP3720855B1 (en) 2021-08-25
MA51020A (fr) 2021-05-26
HUE056667T2 (hu) 2022-02-28
RS62517B1 (sr) 2021-11-30
IL274868A (en) 2020-07-30
HRP20211726T1 (hr) 2022-02-18
MY203080A (en) 2024-06-07
JP2021505584A (ja) 2021-02-18
AR113923A1 (es) 2020-07-01
TW201936198A (zh) 2019-09-16
EA202091139A1 (ru) 2020-11-23
LT3720855T (lt) 2021-11-10
NZ763704A (en) 2026-01-30
CO2020006648A2 (es) 2020-06-09
CN111344291B (zh) 2023-05-05
WO2019110703A1 (en) 2019-06-13
BR112020008583A2 (pt) 2020-10-20
UA126247C2 (uk) 2022-09-07
SA520412155B1 (ar) 2022-06-05
PH12020550785A1 (en) 2021-04-12
SI3720855T1 (sl) 2021-12-31
KR20200097301A (ko) 2020-08-18
CL2020001402A1 (es) 2020-09-21
PT3720855T (pt) 2021-11-03
TWI809014B (zh) 2023-07-21
SG11202005138TA (en) 2020-06-29
JP6941235B2 (ja) 2021-09-29
EP3720855A1 (en) 2020-10-14
PL3720855T3 (pl) 2022-01-24
US20190175605A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
ECSP15014941A (es) Compuestos antivíricos para el vsr
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2020001402A1 (es) Derivados de imidazopiridina y su uso como medicamento.
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles